Prothena Corporation plc $PRTA Stock Holdings Increased by American Century Companies Inc.

American Century Companies Inc. grew its position in Prothena Corporation plc (NASDAQ:PRTA) by 14.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,836 shares of the biotechnology company’s stock after acquiring an additional 4,437 shares during the quarter. American Century Companies Inc. owned approximately 0.06% of Prothena worth $431,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP increased its holdings in shares of Prothena by 22.8% in the 4th quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company’s stock valued at $71,063,000 after acquiring an additional 952,088 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Prothena by 1.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 864,833 shares of the biotechnology company’s stock valued at $11,980,000 after purchasing an additional 10,783 shares during the last quarter. Northern Trust Corp increased its stake in Prothena by 8.5% during the fourth quarter. Northern Trust Corp now owns 404,496 shares of the biotechnology company’s stock valued at $5,602,000 after purchasing an additional 31,841 shares during the last quarter. DCF Advisers LLC increased its stake in Prothena by 88.4% during the first quarter. DCF Advisers LLC now owns 195,000 shares of the biotechnology company’s stock valued at $2,413,000 after purchasing an additional 91,500 shares during the last quarter. Finally, Nuveen LLC bought a new stake in shares of Prothena during the 1st quarter valued at about $1,856,000. 97.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and set a $18.00 price objective on shares of Prothena in a research report on Thursday, August 28th. Bank of America reaffirmed an “underperform” rating on shares of Prothena in a report on Wednesday, May 28th. Royal Bank Of Canada lowered their target price on Prothena from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Tuesday, August 5th. JMP Securities lowered their price objective on Prothena from $29.00 to $11.00 and set a “market outperform” rating for the company in a research note on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Prothena in a research note on Tuesday, August 5th. Four analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Prothena currently has an average rating of “Hold” and a consensus target price of $19.75.

Prothena Stock Up 4.1%

Shares of PRTA opened at $8.55 on Friday. The firm has a 50-day moving average price of $7.32 and a 200 day moving average price of $8.80. The firm has a market capitalization of $460.25 million, a PE ratio of -1.52 and a beta of -0.04. Prothena Corporation plc has a 52-week low of $4.32 and a 52-week high of $22.71.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.75). The company had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%. On average, equities analysts expect that Prothena Corporation plc will post -4.04 EPS for the current year.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.